Trial Profile
Post-licensure Observational Safety Surveillance Study of Quadrivalent Meningococcal ACWY Conjugate Vaccine MenACWY-CRM (MENVEO) in Children 2 Months Through 23 Months of Age
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 27 Jun 2023
Price :
$35
*
At a glance
- Drugs Meningococcal vaccine groups A C Y W-135 conjugate (Primary)
- Indications Meningococcal group A infections; Meningococcal group C infections; Meningococcal group W-135 infections; Meningococcal group Y infections; Meningococcal infections
- Focus Adverse reactions
- Sponsors GlaxoSmithKline; GSK; Novartis Vaccines
- 12 Oct 2019 Results assessing safety of quadrivalent meningococcal conjugate vaccine in infants and toddlers 2 to 23-months old published in the Vaccine
- 12 Dec 2017 Status changed from active, no longer recruiting to completed.
- 10 Apr 2017 Planned number of patients changed from 90 to 121.